MIM
CRNX icon

Monashee Investment Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

Monashee Investment Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-27,371
Closed -$814K – 57
2023
Q3 		$814K Buy
+27,371
New +$564K 0.34% 62
2022
Q3 		– Sell
-95,000
Closed -$1.77M – 57
2022
Q2 		$1.77M Buy
+95,000
New +$1.9M 0.65% 14

Other funds holding CRNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Monashee Investment Management's CRNX Position: Q4 2023 in Review

Monashee Investment Management sold out of Crinetics Pharmaceuticals (CRNX) in Q4 2023, closing a stake of 27,371 shares — an estimated $814K sold.

Monashee Investment Management first reported a position in CRNX in Q2 2022 and held it in 2 quarters. The position peaked at $1.77M in Q2 2022. 181 funds tracked by Wall St. Rank hold CRNX as of Q4 2023.

  • Monashee Investment Management reported no remaining Crinetics Pharmaceuticals position as of Q4 2023 after selling out during the quarter.
  • Monashee Investment Management sold 27,371 Crinetics Pharmaceuticals shares in Q4 2023, an estimated $814K.
  • Monashee Investment Management first reported a position in Crinetics Pharmaceuticals in Q2 2022 and held it in 2 quarters.
  • Monashee Investment Management's Crinetics Pharmaceuticals position peaked at $1.77M in Q2 2022.
  • 181 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q4 2023.

Based on Monashee Investment Management's 13F filing for Q4 2023, filed 12 Feb 2024.